1Nissen SE,Wolski K.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes[J].N Engl J Med,2007,356(24):2457-2471.
2Lago RM,Singh PP,Nesto RW.Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones:A meta-analysis of randomised clinical trials[J].Lancet,2007,370(9593):1129-1136.
3Wertz DA,Chang CL,Sarawate CA,et al.Risk of cardiovascular events and all-cause mortality in patients treated with thiazolidinediones in a managed-care population[J].Circ Cardiovasc Qual Outcomes,2010,3(5):538-545.
4McGuire DK,See R,Abdullah SM,et al.The effect of rosiglitazone on integrated cardiovascular performance,cardiac structure,function and myocardial triglyceride:Trial design and rationale[J].Diab Vasc Dis Res,2009,6(1):43-50.
